ZOVIRAX SWITCH DEFERRAL URGED BY CDC
This article was originally published in The Tan Sheet
Executive Summary
ZOVIRAX SWITCH DEFERRAL URGED BY CDC "until the weight of evidence indicates that its potential public health benefits outweigh the potential negative effects," Phil Pellet, PhD, National Center for Infectious Diseases, told the May 19 FDA public heating on the potential OTC use of systemic acyclovir for genital herpes.